secwatch.observer — SEC 8-K summary
======================================

Issuer:     ADIAL PHARMACEUTICALS, INC. (ADIL)
CIK:        0001513525
Form:       8-K
Filed at:   2025-05-15T23:59:59+00:00
Accession:  0001213900-25-043730
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Adial Pharma Q1 net loss $2.2M; warrants raise $2.75M; AD04 Phase 2 meeting set for July
--------------------------------------------------------------------------------

- Cash $2.4M at March 31; with $2.75M warrant proceeds, runway into Q4 2025.
- Net loss $2.2M vs $6.5M YoY; reduction due to $4.5M 2024 inducement expense not recurring.
- Entered warrant inducement: exercised 3.7M shares at $0.74, gross proceeds ~$2.75M.
- Received six-figure milestone from Adovate for asthma candidate Phase 1; eligible for up to $83M in milestones plus royalties.
- FDA supports 505(b)(2) bridging strategy; End of Phase 2 meeting planned for July 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1513525/000121390025043730/0001213900-25-043730-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1513525/000121390025043730/ea0242253-8k_adial.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-043730

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer